J Clin Neurol.  2005 Oct;1(2):121-133. 10.3988/jcn.2005.1.2.121.

Endogenous Zinc in Neurological Diseases

• Koh JY

• KMID: 1808482
• DOI: http://doi.org/10.3988/jcn.2005.1.2.121

Abstract

The use of zinc in medicinal skin cream was mentioned in Egyptian papyri from 2000 BC (for example, the Smith Papyrus), and zinc has apparently been used fairly steadily throughout Roman and modern times (for example, as the American lotion named for its zinc ore, 'Calamine'). It is, therefore, somewhat ironic that zinc is a relatively late addition to the pantheon of signal ions in biology and medicine. However, the number of biological functions, health implications and pharmacological targets that are emerging for zinc indicate that it might turn out to be 'the calcium of the twenty-first century'. Here neurobiological roles of endogenous zinc is summarized.

Keyword

Ischemia; Stroke; Alzheimer; Amyotrophic lateral sclerosis

MeSH Terms

Amyotrophic Lateral Sclerosis
Biology
Calcium
Ions
Iron
Ischemia
Skin Cream
Stroke
Zinc*
Calcium
Ions
Iron
Zinc

Reference

1. Sandstead HH. Causes of iron and zinc deficiencies and their effects on brain. J Nutr. 2000. 130:347S–349S.

2. Berg JM. Zinc fingers and other metal-binding domains. Elements for interactions between macromolecules. J Biol Chem. 1990. 265:6513–6516.

3. Lock K, Janssen CR. Comparative toxicity of a zinc salt, zinc powder and zinc oxide to Eisenia fetida, Enchytraeus albidus and Folsomia candida. Chemosphere. 2003. 53:851–856.

4. Sensi SL, Yin HZ, Weiss JH. AMPA/kainate receptor-triggered Zn2+ entry into cortical neurons induces mitochondrial Zn2+ uptake and persistent mitochondrial dysfunction. Eur J Neurosci. 2000. 12:3813–3818.

5. Weiss JH, Sensi SL, Koh JY. Zn(2+): a novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci. 2000. 21:395–401.

6. Sensi SL, Ton-That D, Weiss JH. Mitochondrial sequestration and Ca2+-dependent release of cytosolic Zn2+ loads in cortical neurons. Neurobiol Dis. 2000. 10:100–108.

7. Haase H, Maret W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp Cell Res. 2003. 291:289–298.

8. Maret W, Yetman CA, Jiang L. Enzyme regulation by reversible zinc inhibition: glycerol phosphate dehydrogenase as an example. Chem Biol Interact. 2001. 130-132:891–901.

9. Maret W, Jacob C, Vallee BL, Fischer EH. Inhibitory sites in enzymes: zinc removal and reactivation by thionein. Proc Natl Acad Sci U S A. 1999. 96:1936–1940.

10. Choi DW, Koh JY. Zinc and brain injury. Annu Rev Neurosci. 1998. 21:347–375.

11. Frederickson CJ. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol. 1989. 31:145–238.

12. Frederickson CJ, Bush AI. Synaptically released zinc: physiological functions and pathological effects. Biometals. 2001. 14:353–366.

13. Slomianka L, Danscher G, Frederickson CJ. Labeling of the neurons of origin of zinc-containing pathways by intraperitoneal injections of sodium selenite. Neuroscience. 1990. 38:843–854.

14. MASKE H. A new method for demonstrating A and B cells in the islands of Langerhans. Klin Wochenschr. 1955. 33:1058.

15. Ben Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience. 1985. 14:375–403.

16. Li Y, Hough CJ, Frederickson CJ, Sarvey JM. Induction of mossy fiber --> CA3 long-term potentiation requires translocation of synaptically released Zn2+. J Neurosci. 2001. 21:8015–8025.

17. Brown CE, Dyck RH. Rapid, experience-dependent changes in levels of synaptic zinc in primary somatosensory cortex of the adult mouse. J Neurosci. 2002. 22:2617–2625.

18. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003. 26:207–214.

19. Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci U S A. 1999. 96:1716–1721.

20. Ohana E, Segal D, Palty R, Ton-Tat D, Moran A, Sensi SL, et al. A sodium zinc exchange mechanism is mediating extrusion of zinc in mammalian cells. J Biol Chem. 2004. 279:4278–4284.

21. Budde T, Minta A, White JA, Kay AR. Imaging free zinc in synaptic terminals in live hippocampal slices. Neuroscience. 1997. 79:347–358.

22. Varea E, Ponsoda X, Molowny A, Danscher G, Lopez-Garcia C. Imaging synaptic zinc release in living nervous tissue. J Neurosci Methods. 2001. 110:57–63.

23. Perez-Clausell J, Danscher G. Release of zinc sulphide accumulations into synaptic clefts after in vivo injection of sodium sulphide. Brain Res. 1986. 362:358–361.

24. Quinta-Ferreira ME, Matias CM. Hippocampal mossy fiber calcium transients are maintained during long-term potentiation and are inhibited by endogenous zinc. Brain Res. 2004. 1004:52–60.

25. Frederickson CJ, Hernandez MD, Goik SA, Morton JD, McGinty JF. Loss of zinc staining from hippocampal mossy fibers during kainic acid induced seizures: a histofluorescence study. Brain Res. 1988. 446:383–386.

26. Marin P, Israel M, Glowinski J, Premont J. Routes of zinc entry in mouse cortical neurons: role in zinc-induced neurotoxicity. Eur J Neurosci. 2000. 12:8–18.

27. Thompson RB, Maliwal BP, Zeng HH. Zinc biosensing with multiphoton excitation using carbonic anhydrase and improved fluorophores. J Biomed Opt. 2000. 5:17–22.

28. Atar D, Backx PH, Appel MM, Gao WD, Marban E. Excitation-transcription coupling mediated by zinc influx through voltage-dependent calcium channels. J Biol Chem. 1995. 270:2473–2477.

29. Kerchner GA, Canzoniero LM, Yu SP, Ling C, Choi DW. Zn2+ current is mediated by voltage-gated Ca2+ channels and enhanced by extracellular acidity in mouse cortical neurones. J Physiol. 2000. 528(Pt 1):39–52.

30. Yin HZ, Ha DH, Carriedo SG, Weiss JH. Kainate-stimulated Zn2+uptake labels cortical neurons with Ca2+-permeable AMPA/kainate channels. Brain Res. 1998. 781:45–55.

31. Li Y, Hough CJ, Suh SW, Sarvey JM, Frederickson CJ. Rapid translocation of Zn(2+) from presynaptic terminals into postsynaptic hippocampal neurons after physiological stimulation. J Neurophysiol. 2001. 86:2597–2604.

32. Maret W. The function of zinc metallothionein: a link between cellular zinc and redox state. J Nutr. 2000. 130:1455S–1458S.

33. Maret W. Oxidative metal release from metallothionein via zinc-thiol/disulfide interchange. Proc Natl Acad Sci U S A. 1994. 91:237–241.

34. Uchida Y, Taiko K, Titani KIY, Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 aminoacid metallothionein-like protein. Neuron. 1991. 31:337–347.

35. Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci U S A. 1992. 89:6333–6337.

36. Lee JY, Kim JH, Palmiter RD, Koh JY. Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp Neurol. 2003. 184:337–347.

37. Howell GA, Welch MG, Frederickson CJ. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature. 1984. 308:736–738.

38. Li Y, Hough CJ, Suh SW, Sarvey JM, Frederickson CJ. Rapid translocation of Zn(2+ from presynaptic terminals into postsynaptic hippocampal neurons after physiological stimulation. J Neurophysiol. 2001. 86:2597–2604.

39. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD. Disruption of the metallothionein-III gene in mice: analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci. 1997. 17:1271–1281.

40. Lee JY, Kim JH, Palmiter RD, Koh JY. Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp Neurol. 2003. 184:337–347.

41. Peters S, Koh J, Choi DW. Zinc selectively blocks the action of N-methyl-D-aspartate on cortical neurons. Science. 1987. 236:589–593.

42. Paoletti P, Ascher P, Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci. 1997. 17:5711–5725.

43. Low CM, Zheng F, Lyuboslavsky P, Traynelis SF. Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc Natl Acad Sci U S A. 2000. 97:11062–11067.

44. Coughenour LL, Barr BM. Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits. J Pharmacol Exp Ther. 2001. 296:150–159.

45. Manzerra P, Behrens MM, Canzoniero LM, Wang XO, Heidinger V, Ichinose T, et al. Zinc induces a Src family kinase-mediated up-regulation of NMDA receptor activity and excitotoxicity. Proc Natl Acad Sci U S A. 2001. 98:11055–11061.

46. Kim TY, Hwang JJ, Yun SH, Jung MW, Koh JY. Augmentation by zinc of NMDA receptor-mediated synaptic responses in CA1 of rat hippocampal slices: mediation by Src family tyrosine kinases. Synapse. 2002. 46:49–56.

47. Westbrook GL, Mayer ML. Micromolar concentrations of Zn2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature. 1987. 328:640–643.

48. Ruiz A, Walker MC, Fabian-Fine R, Kullmann DM. Endogenous zinc inhibits GABA(A) receptors in a hippocampal pathway. J Neurophysiol. 2004. 91:1091–1096.

49. Xie X, Hider RC, Smart TG. Modulation of GABA-mediated synaptic transmission by endogenous zinc in the immature rat hippocampus in vitro. J Physiol. 1994. 478:75–86.

50. Buhl EH, Otis TS, Mody I. Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. Science. 1996. 271:369–373.

51. Coulter DA. Epilepsy-associated plasticity in gamma-aminobutyric acid receptor expression, function, and inhibitory synaptic properties. Int Rev Neurobiol. 2001. 45:237–252.

52. Shumate MD, Lin DD, Gibbs JW III, Holloway KL, Coulter DA. GABA(A) receptor function in epileptic human dentate granule cells: comparison to epileptic and control rat. Epilepsy Res. 1998. 32:114–128.

53. Banerjee PK, Olsen RW, Snead OC III. Zinc inhibition of gamma-aminobutyric acid(A) receptor function is decreased in the cerebral cortex during pilocarpine-induced status epilepticus. J Pharmacol Exp Ther. 1999. 291:361–366.

54. Murphy JV. Intoxication following ingestion of elemental zinc. JAMA. 1970. 212:2119–2120.

55. Taban CH, Cathieni M, Burkard P. Changes in newt brain caused by zinc water-pollution. Experientia. 1982. 38:683–685.

56. Dethloff GM, Schlenk D, Hamm JT, Bailey HC. Alterations in physiological parameters of rainbow trout (Oncorhynchus mykiss) with exposure to copper and copper/zinc mixtures. Ecotoxicol Environ Saf. 1999. 42:253–264.

57. Yokoyama M, Koh J, Choi DW. Brief exposure to zinc is toxic to cortical neurons. Neurosci Lett. 1986. 71:351–355.

58. Frederickson CJ, Klitenick MA, Manton WI, Kirkpatrick JB. Cytoarchitectonic distribution of zinc in the hippocampus of man and the rat. Brain Res. 1983. 273:335–339.

59. Sloviter RS. A selective loss of hippocampal mossy fiber Timm stain accompanies granule cell seizure activity induced by perforant path stimulation. Brain Res. 1985. 330:150–153.

60. Assaf SY, Chung SH. Release of endogenous Zn2+ from brain tissue during activity. Nature. 1984. 308:734–736.

61. Ueno S, Tsukamoto M, Hirano T, Kikuchi K, Yamada MK, Nishiyama N, et al. Mossy fiber Zn2+ spillover modulates heterosynaptic N-methyl-D-aspartate receptor activity in hippocampal CA3 circuits. J Cell Biol. 2002. 158:215–220.

62. Koh JY, Suh SW, Gwag BJ, He JJ, Shu CY, Choi DW. The role of zinc in selective neuronal death after transient global cerebral ischemia. Science. 1996. 272:1013–1016.

63. Suh SW, Chen JW, Motamedi M, Bell B, Lstiak K, Pons NF, et al. Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury. Brain Res. 2000. 852:268–273.

64. Lee JM, Zipfel GJ, Park KH, He YY, Shu CY, Choi DW. Zinc translocation accelerates infarction after mild transient focal ishcemia. Neuroscience. 2002. 115:871–878.

65. Yin HZ, Sensi SL, Ogoshi F, Weiss JH. Blockade of Ca2+-permeable AMPA/kainate channels decreases oxygen-glucose deprivation-induced Zn2+ accumulation and neuronal loss in hippocampal pyramid neurons. J Neurosci. 2002. 22:1273–1279.

66. Suh SW, Garnier P, Aoyama K, Chen Y, Swanson RA. Zinc release contributes to hypoglycemia-induced neuronal death. Neurobiol Dis. 2004. 16:538–545.

67. Frederickson CJ, Hernandez MD, McGinty JF. Translocation of zinc may contribute to seizure-induced death of neurons. Brain Res. 1989. 480:317–321.

68. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human amyloid precursor protein transgenic mice. Neurobiol Aging. 2004. in press.

69. Lee JY, Cole TB, Palmiter RD, Koh JY. Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: evidence against synaptic vesicle origin. J Neurosci. 2000. 20:RC79.

70. Frederickson CJ, Suh SW, Koh JT, Cha YK, Thompson RB, LaBuda CJ, et al. Depletion of intracellular zinc from neurons by use of an extracellular chelator in vivo and in vitro. J Histochem Cytochem. 2000. 50:1659–1662.

71. Wei G, Hough CJ, Li Y, Sarvey JM. Characterization of extracellular accumulation of Zn(2+) during ischemia and reperfusion of hippocampus slices in rat. Neuroscience. 2004. 125:867–877.

72. Sunderman FW Jr. The influence of zinc on apoptosis. Ann Clin Lab Sci. 1995. 25:134–142.

73. Kim EY, Koh JY, Kim YH, Sohn S, Joe EH, Gwag BJ. Zn2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur J Neurosci. 1999. 11:327–334.

74. Sensi SL, Yin HZ, Weiss JH. Glutamate triggers preferential Zn2+ flux through Ca2+ permeable AMPA channels and consequent ROS production. Neuroreport. 1999. 10:1723–1727.

75. Noh KM, Kim YH, Koh JY. Mediation by membrane protein kinase C of zinc-induced oxidative neuronal injury in mouse cortical cultures. J Neurochem. 1999. 72:1609–1616.

76. Kim YH, Kim EY, Gwag BJ, Sohn S, Koh JY. Zinc-induced cortical neuronal death with features of apoptosis and necrosis: mediation by free radicals. Neuroscience. 1999. 89:175–182.

77. Seo SR, Chong SA, Lee SL, Sung JY, Ahn YS, Chong KC, et al. Zn2+-induced ERK activation mediated by reactive oxygen species cause cell death in differentiated PC12 cells. J Neurochem. 2001. 78:600–610.

78. Noh KM, Koh JY. Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci. 2000. 20:RC111.

79. Lobner D, Canzoniero LM, Manzerra P, Gottron F, Yang H, Knudson M, et al. Zinc-induced neuronal death in cortical neurons. Cell Mol Biol. 2000. 46:797–806.

80. McCabe MJ Jr, Jiang SA, Orrenius S. Chelation of intracellular zinc triggers apoptosis in mature thymocytes. Lab Invest. 1993. 69:101–110.

81. Ahn YH, Kim YH, Hong SH, Koh JY. Depletion of intracellular zinc induces protein synthesis-dependent neuronal apoptosis in mouse cortical culture. Exp Neurol. 1998. 154:47–56.

82. Park JA, Lee JY, Sato TA, Koh JY. Co-induction of p75NTR and p75NTR-associated death executor in neurons after zinc exposure in cortical culture or transient ischemia in the rat. J Neurosci. 2000. 20:9096–9103.

83. Mukai J, Hachiya T, Shoji-Hoshino S, Kimura MT, Nadano D, Suvanto P, et al. NADE, a p75NTR-associated cell death executor, is involved in signal trnsduction mediated by the common neurotrophin receptor p75NTR. J Biol Chem. 2000. 275:17566–17570.

84. Jiang D, Sullivan PG, Sensi SL, Steward O, Weiss JH. Zn(2+) induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria. J Biol Chem. 2001. 276:47524–47529.

85. Yi JS, Lee SK, Sato TA, Koh JY. Co-induction of p75NTR and the associated death executor NADE in degenerating hippocampal neurons after kainate-induced seizures in the rat. Neurosci Lett. 2003. 347:126–130.

86. Aravindakumar CT, Ceulemans J, De Ley M. Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. Biochem J. 1999. 344:253–258.

87. Maret W. The function of zinc metallothionein: a link between cellular zinc and redox state. J Nutr. 2000. 130:1455S–1458S.

88. St Croix CM, Wasserloos KJ, Dineley KE, Reynolds IJ, Levutan ES, Pitt BR. Nitric oxide-induced changes in intracellular zinc homeostasis are mediated by metallothionein/thionein. Am J Physiol Lung Cell Mol Physiol. 2002. 282:L185–L192.

89. Jacob C, Maret W, Vallee BL. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc Natl Acad Sci U S A. 1998. 95:3489–3494.

90. Maret W. The function of zinc metallothionein: a link between cellular zinc and redox state. J Nutr. 2000. 130:1455S–1458S.

91. Frederickson CJ, Cuajungco MP, LaBuda CJ, Suh SW. Nitric oxide causes apparent release of zinc from presynaptic boutons. Neuroscience. 2002. 115:471–474.

92. Kim YH, Koh JY. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly (ADP-ribose) polymerase activation and cell death in cortical culture. Exp Neurol. 2002. 177:407–418.

93. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A. 1999. 96:13978–13982.

94. Szabo C, Dawson VL. Role of poly (ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci. 1998. 19:287–298.

95. Sheline CT, Wang H, Cai AL, Dawson VL, Choi DW. Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity. Eur J Neurosci. 2003. 18:1402–1409.

96. Terry RD, Katzman R. Senile dementia of the Alzheimer type. Annals Neurol. 1983. 14:497–506.

97. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984. 120:885–890.

98. Masters CL, Simms G, Weinzman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985. 82:4245–4249.

99. Bush AI, Pettingell WH Jr, Paradis MD, Tanzi RE. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem. 1994. 269:12152–12158.

100. Bush AI, Pettingell WH, Multhaup G, di Paradis M, Vonsattel JP, Gusella JF, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 1994. 265:1464–1467.

101. Frederickson CJ, Maret W, Cuajungco MP. Zinc and excitotoxic brain injury: a new model. Neuroscientist. 2004. 10:18–25.

102. Liu ST, Howlett G, Barrow CJ. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry. 1999. 38:9373–9378.

103. Esch FS, Keim PS, Beattie ES, Blchor RW, Cultwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990. 248:1122–1124.

104. Huang X, Atwood CS, Moir RD, Hartshom MA, Vonsattel JP, Tanzi RE, et al. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem. 1997. 272:26464–26470.

105. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacurra VM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998. 273:12817–12826.

106. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry. 2000. 39:7024–7031.

107. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem. 2000. 75:1219–1233.

108. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998. 158:47–52.

109. Opazo C, Hwang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem. 2002. 277:40302–40308.

110. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry. 2003. 42:2768–2773.

111. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 2002. 277:44670–44676.

112. Huang X, Cuajungco MP, Atqood CS, Hartshom MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999. 274:37111–37116.

113. Huang X, Atwood CS, Hartshom MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 1999. 38:7609–7616.

114. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med. 2001. 30:447–450.

115. Atwood CS, Huang X, Khani A, Scarpa RC, Kim YS, Moir RD, et al. Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol. 2000. 46:777–783.

116. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KO, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry. 2004. 43:560–568.

117. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, et al. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem. 2003. 278:42959–42965.

118. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MS, Beyruether K, et al. Soluble pool of Ab amyloid as a determinant of severity of neurodegenertion in Alzheimer's disease. Ann Neurol. 1996. 46:860–866.

119. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 1999. 274:23223–23228.

120. Head E, Garzon-Rodriguez M, Johnson JK, Lott IT, Cotman CW, et al. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis. 2001. 8:792–806.

121. Turnbull S, Tabner BJ, El Agnaf OM, Twyman LJ, Allsop D. New evidence that the Alzheimer beta-amyloid peptide does not spontaneously form free radicals: an ESR study using a series of spin-traps. Free Radic Biol Med. 2001. 30:1154–1162.

122. Hensley K, Hall N, Subaramanian R, Cole P, Askenov M, Gabbita SP, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem. 1995. 65:2146–2156.

123. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harnis PL, Siedlack SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem. 1998. 70:2212–2215.

124. Cuajungco MP, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem. 2000. 275:19439–19442.

125. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A. 2002. 99:7705–7710.

126. Lee JY, Kim JH, Hong SH, Lee JY, Cherny RA, Bush AI, et al. Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc in mouse brain. J Biol Chem. 2004. 279:8602–8607.

127. Sillevis Smitt PA, Mulder TP, Verspaget HW, Blaauwgeers HG, Troost D, de Jong JM. Metallothionein in amyotrophic lateral sclerosis. Biol Signals. 1994. 3:193–197.

128. Sillevis Smitt PA, Blaauwgeers HG, Troost D, de Jong JM. Metallothionein immunoreactivity is increased in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett. 1992. 144:107–110.

129. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996. 13:43–47.

130. Liochev SI, Chen LL, Hallewell RA, Fridovich I. Superoxide-dependent peroxidase activity of H48Q: a superoxide dismutase variant associated with familial amyotrophic lateral sclerosis. Arch Biochem Biophys. 1997. 346:263–268.

131. Singh RJ, Karoui H, Gunther MR, Beckman JS, Mason RP, Kalyanaraman B. Reexamination of the mechanism of hydroxyl radical adducts formed from the reaction between familial amyotrophic lateral sclerosis-associated Cu, Zn superoxide dismutase mutants and H2O2. Proc Natl Acad Sci U S A. 1998. 95:6675–6680.

132. Roe JA, Wiedau-Pazos M, Moy VN, Goto JJ, Gralla EB, Valentine JS. In vivo peroxidative activity of FALS-mutant human CuZnSODs expressed in yeast. Free Radic Biol Med. 2002. 32:169–174.

133. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science. 1999. 286:2498–2500.

134. Gong YH, Elliott JL. Metallothionein expression is altered in a transgenic murine model of familial amyotrophic lateral sclerosis. Exp Neurol. 2000. 162:27–36.

135. Nagano S, et al. Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur J Neurosci. 2001. 13:1363–1370.

136. Puttaparthi K, Gitomer WL, Krishnan U, Son M, Rajendra B, Elliott JL. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J Neurosci. 2002. 22:8790–8796.

137. Cherny RA, Atwood CS, Xilinas ME, Gay DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001. 30:665–676.

138. Regland B, Lehmann W, Abedini I, Blennon K, Jonsson M, Karlson I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 2001. 12:408–414.

139. Ritchie CW, Bush AI, Mackinnon K, Mcfarrens S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003. 60:1685–1691.

140. Canzoniero LM, Manzerra P, Sheline CT, Choi DW. Membrane-permeant chelators can attenuate Zn2+-induced cortical neuronal death. Neuropharmacology. 2003. 45:420–428.

141. Sensi SL, Ton-That D, Weiss JH. Mitochondrial sequestration and Ca2+-dependent release of cytosolic Zn2+ loads in cortical neurons. Neurobiol Dis. 2002. 10:100–108.

142. Noh KM, Kim YH, Koh JY. Mediation by membrane protein kinase C of zinc-induced oxidative neuronal injury in mouse cortical cultures. J Neurochem. 1999. 72:1609–1616.

143. Sheline CT, Behrens MM, Choi DW. Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. J Neurosci. 2000. 20:3139–3146.

144. Kelland EE, Kelly MD, Toms NJ. Pyruvate limits zinc-induced rat oligodendrocyte progenitor cell death. Eur J Neurosci. 2004. 19:287–294.

145. Lee JY, Kim YH, Koh JY. Protection by pyruvate against transient forebrain ischemia in rats. J Neurosci. 2001. 21:RC171.

146. Yoo MH, Lee JY, Lee SE, Koh JY, Yoon YH. Protection by Pyruvate of Rat Retinal Cells against Zinc Toxicity In Vitro, and Pressure-Induced Ischemia In Vivo. Invest Ophthalmol Vis Sci. 2004. 45:1523–1530.

147. Chang I, Cho N, Koh JY, Lee MS. Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes. Diabetologia. 2003. 46:1220–1227.

148. Dobsak P, Courderot-Masuyer C. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol. 1999. 34:651–659.

149. Albers GW. Advances in intravenous thrombolytic therapy for treatment of acute stroke. Neurology. 2001. 57:5 Suppl 2. S77–S81.

150. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature. 1996. 384:123–124.

151. Kim YH, Park JH, Hong SH, Koh JY. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science. 1999. 284:647–650.

152. Siddiq MM, Tsirka SE. Modulation of zinc toxicity by tissue plasminogen activator. Mol Cell Neurosci. 2004. 25:162–171.